Related Experiment Video
Updated: May 7, 2026
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Platelet function testing to time surgery in patients on dual antiplatelet therapy?
1Elisabeth Mahla, M.D., Department of Anesthesiology and Intensive Care, Medicine, Research Unit for Perioperative Platelet, Function, Medical University of Graz, Auenbruggerplatz 29, 8036 Graz, Austria, Tel. +43/316/38 51 30 27, Fax +43/316/38 51 32 67,
Hamostaseologie
|September 28, 2013
Summary
For patients on P2Y12 inhibitors needing surgery, fixed waiting times may not be ideal. Platelet function testing could personalize surgical timing to balance bleeding and ischemic risks.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Surgical Science
Background:
- Current guidelines recommend delaying surgery 5-7 days after P2Y12 inhibitor cessation.
- Inter-individual variability in platelet inhibition challenges fixed waiting periods.
- High risk of ischemic events may necessitate earlier surgery.
Purpose of the Study:
- To review P2Y12 inhibitor effects on platelet function.
- To discuss surgery-related bleeding risks.
- To explore the role of platelet function analysis in timing surgery.
Main Methods:
- Literature review of P2Y12 inhibitors, platelet reactivity, and surgical bleeding.
- Analysis of current guideline recommendations.
- Discussion of platelet function assays and bleeding cutoffs.
Main Results:
- P2Y12 inhibitors (clopidogrel, ticagrelor, prasugrel) significantly inhibit platelet function.
- Variability exists in patient response to these drugs.
- Optimal platelet function assays and bleeding thresholds for surgery remain undefined.
Conclusions:
- Personalized surgical timing based on platelet function testing is a potential alternative to fixed waiting periods.
- Further multicenter trials are needed to define optimal assays and cutoffs.
- Balancing ischemic and bleeding risks is crucial in P2Y12 inhibitor-treated patients undergoing surgery.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...